Table 1 summarizes the main preclinical studies of IDH-targeted agents in glioma mouse models, Table 2 shows the clinical trials with available data so far, while in Table 3 are presented the main ongoing clinical studies for IDH-mutant gliomas. The gene discussed is IDH1; the disease is central nervous system cancer.